300347.SZ
300347.SZ
CNE100001KV8
TIGERMED
Loading chart...

Company Profile

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

Related stocks

3347.HK
3347.HK • China
TIGERMED
44.56 HKD
4.89B USD 1Y +3.2%
603127.SS
603127.SS • China
JOINN LABORATORIES (CHINA) CO L
52.6 CNY
5.9B USD 1Y +47.6%
300676.SZ
300676.SZ • China
BGI GENOMICS
45.47 CNY
2.85B USD 1Y -9.3%
SHL.AX
SHL.AX • Australia
SONIC HLTH FPO [SHL]
18.65 AUD
6.44B USD 1Y -13%
603882.SS
603882.SS • China
GUANGZHOU KINGMED DIAGNOSTICS G
28.82 CNY
2B USD 1Y -3.4%
6127.HK
6127.HK • China
JOINN
31.32 HKD
2.99B USD 1Y +45%
300244.SZ
300244.SZ • China
D.A. DIAGNOSTICS
20.4 CNY
1.91B USD 1Y +24.4%
SAILIFE.NS
SAILIFE.NS • India
SAI LIFE SCIENCES LIMITED
1,487.9 INR
3.27B USD 1Y +74.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
50.6% p.a.
Max Drawdown (5Y)
-79.3%
Sharpe Ratio (5Y)
-0.44
Beta Factor
0.43
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 501.6 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (50.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -82.3% in the extended horizon.
ende